

Research article

Open Access

Expression of alternatively spliced isoforms of human Sp7 in osteoblast-like cells

Maria-athina Milona¹, Julie E Gough² and Alasdair J Edgar*³

Address: ¹Department of Cell Biology and Genetics, Faculty of Medicine, Erasmus Medical Center, Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands, ²Manchester Materials Science Centre, University of Manchester and UMIST, Grosvenor St., Manchester, M1 7HS, United Kingdom and ³Department of Adult Oral Health, The Institute of Dentistry, Barts and The London, Queen Mary's School of Medicine and Dentistry, Turner Street, London, E1 2AD, United Kingdom

Email: Maria-athina Milona - athinam@well.ox.ac.uk; Julie E Gough - j.gough@umist.ac.uk; Alasdair J Edgar* - a.j.edgar@qmul.ac.uk

* Corresponding author

Published: 07 November 2003

Received: 23 June 2003

BMC Genomics 2003, 4:43

Accepted: 07 November 2003

This article is available from: <http://www.biomedcentral.com/1471-2164/4/43>

© 2003 Milona et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: Osteogenic and chondrocytic differentiation involves a cascade of coordinated transcription factor gene expression that regulates proliferation and matrix protein formation in a defined temporo-spatial manner. Bone morphogenetic protein-2 induces expression of the murine Osterix/Specificity protein-7 (Sp7) transcription factor that is required for osteoblast differentiation and bone formation. Regulation of its expression may prove useful for mediating skeletal repair.

Results: Sp7, the human homologue of the mouse Osterix gene, maps to 12q13.13, close to Sp1 and homeobox gene cluster-C. The first two exons of the 3-exon gene are alternatively spliced, encoding a 431-residue long protein isoform and an amino-terminus truncated 413-residue short protein isoform. The human Sp7 protein is a member of the Sp family having 78% identity with Sp1 in the three, Cys2-His2 type, DNA-binding zinc-fingers, but there is little homology elsewhere. The Sp7 mRNA was expressed in human foetal osteoblasts and craniofacial osteoblasts, chondrocytes and the osteosarcoma cell lines HOS and MG63, but was not detected in adult femoral osteoblasts. Generally, the expression of the short (or beta) protein isoform of Sp7 was much higher than the long (or alpha) protein isoform. No expression of either isoform was found in a panel of other cell types. However, in tissues, low levels of Sp7 were detected in testis, heart, brain, placenta, lung, pancreas, ovary and spleen.

Conclusions: Sp7 expression in humans is largely confined to osteoblasts and chondrocytes, both of which differentiate from the mesenchymal lineage. Of the two protein isoforms, the short isoform is most abundant.

Background

The osteoblast is the precursor of the osteocyte, the bone-forming cell, [1]. The ability to regulate osteoblast proliferation and subsequent differentiation might provide a useful cell source for tissue engineering and repair [2-4]. The murine transcription factor Osterix is required for

osteoblast differentiation and bone formation since in Osterix null mice no bone formation occurs [5]. To further elucidate the molecular basis of osteoblast-specific gene expression and differentiation we examined the sequence and expression of the human homologue of Osterix transcription factor, Specificity protein-7 (Sp7).

Osteoblasts express high levels of a number of extracellular matrix proteins such as type α 1 collagen, type α 2(II) collagen, bone sialoprotein, osteopontin, fibronectin, and osteocalcin required for mineralization [6,7]. Control of their expression is regulated by a number of transcription factors such as runt-related transcription factor-2/core binding factor alpha1 subunit-1 (Runx2/Cbfa1) [7], Nmp4 [8], Aj18 [9,10].

The Runx2/Cbfa1 is regarded as the master transcription factor for osteoblast differentiation since osteoblast differentiation is arrested in both endochondral and intramembranous skeletons in Runx2/Cbfa1 null mice [11–13]. In these Runx2/Cbfa1 null mice Sp7/Osterix is not expressed, whereas in Sp7/Osterix null mice Runx2/Cbfa1 is expressed, suggesting that Runx2/Cbfa1 acts upstream of Sp7/Osterix [5]. During bone development the mineralised cartilage matrix of the endochondral skeletal is invaded by preosteoblasts derived from mesenchymal cells. In Sp7/Osterix null mice these Runx2/Cbfa1 positive preosteoblast cells do not deposit bone matrix and still express chondrocyte marker genes suggesting that they have the potential to develop into chondrocyte or osteoblasts. Sp7/Osterix regulates the expression of a number of important osteoblast genes such as osteocalcin, osteonectin, osteopontin, bone sialoprotein and type I collagen. Sp7/Osterix was first identified by its induction in the murine pluripotent myoblast C2C12 cell line stimulated with bone morphogenetic protein-2 (BMP-2) and is similarly upregulated in bone marrow stromal cells and chondrocytes [4,5,14]. In bone marrow stromal cells from COX-2 knockout mice Osterix expression is reduced compared to wild-type mice and can be recovered by the addition of prostaglandin E₂, indicating that COX-2 mediated skeletal repair involves Sp7/Osterix [4].

Sp7 belongs to the Sp subgroup of the Krüppel-like family of transcription factors (XKLF), that are characterised by a three zinc-finger DNA-binding domain that is located towards the carboxy-terminus of the protein [15–17]. In mammals, 6 other specificity proteins, Sp1–Sp6, have been identified and characterised to date. Outside the zinc-finger DNA-binding domain, the homology between the proteins is much less and often has no significant homology at all. The Sp proteins contain central activation domains that are often glutamine-rich or serine/threonine-rich [17]. Some genes contain a TATA box in their promoters that is involved in binding the transcription factor TFIID and the subsequent initiation of transcription. However, other genes lack a TATA box, and instead contain another major eukaryotic promoter element, the GC-box with the consensus sequences GGGCGG [18]. The Specificity protein-1 (Sp1) is a ubiquitously expressed transcription factor that binds the GC-box [19] and assists the further binding of TFIID for the initiation of transcrip-

tion. Sp2 shows the lowest level of similarity with the other Sp proteins, being restricted only to the DNA-binding domain, and binds to the GT-box rather than the GC-box [18]. Sp3 is ubiquitously expressed. However, it is involved in the control of transcription of a number of tissue-specific genes [20]. Sp3 null mice suffer from a lack of ossification, impaired bone formation, decrease in the expression of osteocalcin, an osteoblast specific gene, being associated with a delay in osteoblast differentiation [17]. In these mice expression of Runx2/Cbfa1 was not affected, suggesting that Sp3 is involved in a Runx2/Cbfa1-independent regulation of osteoblast differentiation. Sp1 and Sp3 may compete for the same GC-boxes as Sp3 was found to suppress the transcriptional activator function of Sp1 by binding to Sp1 specific sites [21]. Sp1 and Sp3 are also associated with chondrocyte de-differentiation by regulating the α 1(II) procollagen gene (COL2A1) [22,23]. Type II collagen is a specific marker of chondrocyte differentiation and chondrocytes can de-differentiate and turn in to osteoarthritic chondrocytes by reducing the production of type II collagen and increasing the production of types I and III collagen. Here, Sp1 was an activator of COL2A1 transcription, whilst Sp3 acted as a repressor. Sp4, a transcriptional activator, is highly expressed in tissues of the central nervous system [20]. Sp5 only shares homology with Sp1 in the DNA-binding domain, binding the GC-box with high affinity and is expressed during early development, mediating the process of gastrulation and axial elongation [24]. Currently, only the sequences of human and mouse Sp6 are known (GenBank accession numbers AK127850 and AK029830 respectively). Here we describe the Sp7 transcription factor, the human homologue of Osterix and identify two alternatively spliced isoforms.

Results

Human Sp7 cDNAs

We cloned two human Sp7 cDNA clones by RT-PCR from foetal osteoblast RNA and determined their sequence (Fig. 1). The clones differed at their 5' termini utilising two different first exons that are alternatively spliced. Clone 1 utilises exon 1B and encodes the long or alpha protein isoform of Sp7 (Fig. 1B)(GenBank accession No. AY150673). Clone 2 utilises exon 1A which is untranslated, and encodes the short or beta protein isoform (Figs. 1A and 2B) (GenBank accession No. AY150674). The first ATG codon of clone 1 is in excellent sequence consensus for an initiation methionine having an adenosine at -3 and a guanosine at +4, and that of clone 2 is in good sequence consensus having a guanosine at -3 [25]. The sequence of clone 1, encoding the long protein isoform, is similar to another GenBank clone (accession No. AF477981, B.W. Ganss, unpublished) which is longer and contains a potential 3' polyadenylation signal sequence.

(A) 5'UTR of short protein isoform

1 acccggttgctgcactctccctgccagacctccagagaggagactcgggacagccagccccaggttcccccag 75

(B) Long protein isoform

-46 tctctccatctgctggctccttgggaccggttccccagcctcagg
 1 **atg**gcgctcctcctgcttgacgaggaagttcactatggctccagtcctccctggccatgctgacggcagcgtgcagcaaatgggtggctct
M A S S L L E E E V H Y G S S P L A **M** L T A A C S K F G G S 30
 91 agccctctgctgggactcaacaactctgggcaaacgagccacaaag aagccgtactctgtgggcagtgacctttcagcctccaaaaccatg
 S P L R D S T T L G K A G T K K P Y S V G S D L S A S K T M 60
 181 ggggatgcttatccagccccctttacaagcactaatgggctcctttcacctgcaggcagctcctccagcaccacactcaggctatgctaat
 G D A Y P A P F T S T N G L L S P A G S P P A P T S G Y A N 90
 271 gattaccctccttttccactcattccctgggcccacagggcaccagaccctgggctactagtgcccaaggggacacagctcttctgac
 D Y P P F S H S F P G P T G T Q D P Y G L L V P K G H S S S D 120
 361 tgtctgccagtgctacacctctctggacatgacacaccctatggctcctgtgtacaaggcaggcatccatgcaggcatttcaccagggc
 C L P S V Y T S L D M T H P Y G S W Y K A G I H A G I S P G 150
 451 ccaggcaaacactcctactcctgggtgggatatgcaccctggaggcaactggctaggtgggtgggacagggccaggggtgatgggtgcaaggg
 P G N T P T P W W D M H P G G N W L G G G Q G Q G D G L Q G 180
 541 acactgccacaggtccagctcagcctcactgaacccccagctgccacactaccatctgactttgctccccttaaccagccccctac
 T L P T G P A Q P P L N P Q L P T Y P S D F A P L N P A P Y 210
 631 ccagctccccctcttgcaaccagggccccagcctcttggcccaagatgtctataaaccaagggcagtggggaaatagtgggcagcta
 P A P H L L Q P G P Q H V T G P Q D V Y K P K A V G H S S S D 240
 721 gaagggagtggtggagccaaacccccacggggtgcaagcactgggggtagtggtggatagggggcagtggggacagggcgctcctcctgc
 E G S G G A K P P R G A S T G G S G G Y G G S G A G R S S C 270
 811 gactgcctaatggcaggagctagagcggctgggagcagcagcggctgggctgcggaagaagccatccacagctgccacatccctggc
 D C P N C Q E L E R L G A A A A G L R K K P I H S C H I P G 300
 901 tgcggcaaggtgatggcaaggtctgcacctgaagggccacttgcgctggcacacaggcgagagggccttctgctgcaactggctcttc
 C G K V Y G K A S H L K A H L R W H T G E R P F V C N W L F 330
 991 tgcggcaagaggttccactcgttcgggatgagctggagcgtcatgtgcccactcacaccgggagaagaagttccactgcctgctctgctcc
 C G K R F T R S D E L E R H V R T H T R E K K F T C L L C S 360
 1081 aagcgctttaccgaagcgaccacctgagcaaacaccagcgcaccatggagaaccagggcccggtccccctcccagtgggcccaaggag
 K R F T R S D H L S K H Q R T H G E P G P G P P S G P K E 390
 1171 ctgggggagggccgcagcagcgggggaagaggagccagtcagacgcccagccttctgctcgcagcaacccccagagaaagccctgga
 L G E G R S T G E E E A S Q T P R P S A S P A T P E K A P G 420
 1261 ggcagccctgagcagagcaacttgctggagatc**tga**gcccgggtggaaggtctcccacccccagggctgcctgacagctctcttggctct
 G S P E Q S N L L E I * 431

Figure 1


Translation of the human Sp7 cDNA sequences. (A) Sequence of 5' untranslated alternatively spliced exon 1A encoding the short protein isoform. (B) Sequence encoding long protein isoform. The exon/exon boundaries (shown in blue bold type and underlined) were determined by comparison with the sequence of genomic DNA clone RP11-147A18. The atg/methionine start codon for the long protein isoform is shown in bold and coloured red and that of the short protein isoform coloured pink. The ORF stop codon, **tga**, is shown in bold and coloured red and is indicated by a red asterisk (*).

Two silent polymorphisms, nucleotides 1098 (agt>agc, Ser-366) and 1128 (cac>cat, His-376) are present.

Human Sp7 gene

The location and structure of the human Sp7 gene was identified by blast searches of the human genome using the two human cDNA sequences Sp7/Osx cDNA. It is located on genomic DNA clone RP11-147A18 (GenBank accession No. AC021103, Genome Sequencing Center, St. Louis, USA). The human Sp7 gene maps to 12q13.13 and neighbours the Sp1 gene, being 57 kb apart (Fig. 2A). These two genes are also linked to the homeobox gene cluster HOX C, being approximately 0.4 Mbp away (Fig.

2A). The human Sp7 gene spans 9.7 kb and lacks a CpG island, a characteristic of genes that do not have a house-keeping role. It has three exons (Fig. 2B). However, the first two exons are alternatively spliced, being separated by the 392 bp intron 1a, followed by the much longer, 6205 bp intron 1b. All splice donor/acceptor sites contained consensus GT/AT dinucleotides. An analysis of the human Sp7 promoter region identified certain potential cis-regulatory sites (Fig. 2C) that are conserved in both the mouse and rat Sp7/Ost promoters (located on mouse supercontig Mm15_WIFeb01_286, Sanger Centre, U.K. and rat chromosome 7q35, accession number AC097309, Human Genome Sequencing Center, Houston, USA).

**Figure 2**

Chromosomal localisation and gene structure of the human Sp7 gene. (A) Sp7 localises to 12q13 and the genes neighbouring Sp7 are the TAR (HIV) RNA binding protein 2, TARBP2; Specificity protein 1, Sp1; Specificity protein 7, Sp7; Aladin, Achalasia, adrenocortical insufficiency gene, AAAS; ATP5G1; SMUG1 and the HOX C 8–13 genes. (B) The human genomic sequence corresponding to the Sp7 cDNA is located on clone RP11-147A18 (accession AC021103) and has three exons. The ORF is indicated by closed boxes. The sequences around the initiation methionine codons (coloured blue) are shown, with those nucleotides corresponding to the Kozak consensus sequence coloured red. The stop codon and the double polyadenylation signal sequence are also shown. The size of the exons and introns are indicated. (C) The promoter region preceding exon 1a contains an S8 homeobox gene and Runx2/Cbfa1 potential cis-regulatory sites that are conserved in the mouse and rat Sp7 promoters. The promoter region preceding exon 1b contains a potential NF-Y CCAAT box binding site. The potential start of transcription is labelled TC and that of translation, TL. Positions are labelled relative to the start of translation. The Runx2/Cbfa1 and NF-Y sites are on the negative strand, (-).

Binding sites for the S8 homeobox gene and core-binding factor alpha-1 (Cbfa1/Osf2/Runx2) (also called an osteocalcin-specific element 2, OSE2) are located approximately 90–100 bp upstream of exon 1a. The S8 site is on the plus strand and partially overlaps with the Runx2/Cbfa1 site on the negative strand. There is a conserved inverted CCAAT box, a potential nuclear factor Y (NF-Y) binding site [26] approximately 115–125 bp upstream of exon 1b.

Comparison of the human and rodent Sp7 protein sequences

The ORF of clone 1 encodes the 431 residue alpha protein with a 44,994 Da molecular mass and an isoelectric point 8.67. The human Sp7 protein is very similar to that of mouse [5] and rat (accession number BK001412) having 95% identity and 99% similarity, with an insertion of 3 residues in the human amino-terminal (Fig. 3). The ORF of clone 2 starts at the second ATG of the clone 1, thereby




Figure 3
 Sequence comparison of the human and rodent Sp7 proteins. *Homo sapiens*, Hs; *Mus musculus*, Mm and *Rattus norvegicus*, Rn. Residues conserved with the mouse protein are shown by (*), strongly conserved residues by (:), and weakly conserved residues by (.). Residues are colour coded: basic, DE, blue; acidic, KR, pink; polar, CGHNQSTY, green and hydrophobic, AFILMPVW, red. The start of translation for the short protein isoforms is indicated by a red **M**. A repetitive motif, GSSPL, is highlighted in yellow. The proline rich domain is underlined. A putative nuclear localization signal is indicated, NLS. By comparison with Sp1, those residues under the alignment illustrate the 3 zinc finger structures, coloured blue, green and red, with those Cys and His residues involved in co-ordinating the zinc ion shown in bold, those residues involved in stabilising the fold in *italics* and those residues involved in DNA binding.




Figure 4

Dendrogram showing the relatedness of human Sp7 protein, HsSp7, to other Sp7 proteins from different species and to other members of the human Sp protein family. The predicted relationships were obtained using the Clustal algorithm and drawn using Treeview. The species are: *Homo sapiens*, Hs; *Mus musculus*, Mm; *Rattus norvegicus*, Rn; The proteins and their length and accession numbers are: Sp1 (785 aa, sp_P08047); Sp2 (613 aa, gb_AAA36629); Sp3 (713 aa, gb_AAL58086); Sp4 (784 aa, NP_003103); Sp5, (398 aa, EST contiguous sequence homologous to mouse Sp5, NP_071880); Sp6 (376 aa, translation of gb_AK127707). The tree was rooted with a more distant member of the Sp/Krüppel-like factor family, the human TGF-beta inducible early protein, TGF-beta-IEG (480 aa, AAC50340) as an outgroup. The three Sp7 proteins are most closely related to Sp6.

omitting the first 18 residues and encodes the beta protein. The beta transcripts are evolutionarily conserved being found in mouse [27] and rat (accession numbers BAC36774 and BK001413, respectively). Consistent with the importance of Sp7 in osteoblast function the Sp7 gene is also expressed in other vertebrates. Homologous ESTs from the frog, *Xenopus neurula*, (accession No. BJ039202) and Zebrafish, *Danio rerio* (accession No. BE557403) were identified by database searches, but invertebrate homologues were not found.

The protein contains three classical zinc finger structures (residues 294–376) of the Cys2-His2 type where the conserved cysteine residues in two short beta-sheets and the histidine residues in an alpha-helix tetrahedrally co-ordinate a zinc ion. The amino terminal part of the helix binds the major groove in DNA binding zinc fingers. These fingers in Sp7 can be described by the motifs *HxCxxxxCxxx-YxKxxHLxAHxxxH*, *FxCxxxxCxxxFxRxxELxRHxxxH* and *FxCx-xCxxxFxRxxHLxKHxxxH* for fingers 1 to 3 respec-

tively, where those hydrophobic residues in italics are important for the stability of the fold, and those underlined are likely to bind DNA [28]. These zinc finger motifs are highly homologous to those present in the Specificity proteins 1 and 3 and similar to other Krüppel family transcription factors [15,18]. The most similar human protein to Sp7 is Sp6 (Fig. 4). A basic region, RKK (residues 289–291), is similar to the nuclear localization signal of the related immediate-early transcription factor, Egr-1 [29].


The protein is glycine and proline rich. The proline rich region (20% proline, residues 65–249) is involved in strong transcriptional activation [5]. Apart from the zinc-finger domain, the protein lacks any similarity to known domains. There are two copies of a GSSPL motif of unknown function at the amino-terminus of the long protein isoform and the short protein isoform possess one alpha-helix/GSSPL motif.

Tissue and cellular distribution of human Sp7 mRNA

The expression of both long and short isoforms of Sp7 in osteoblast cell types was examined by RT-PCR using primers specific for each isoform (Fig. 5A). The Sp7 short protein isoform was expressed in foetal and craniofacial osteoblasts, chondrocytes and the osteosarcoma cell lines HOS and MG63, but was below the limit of detection in adult osteoblasts. In general, the expression of the Sp7 long protein isoform was much lower than the short protein isoform, being found in foetal and craniofacial osteoblasts, and the osteosarcoma cell lines HOS and MG63, but was not found in adult osteoblasts and chondrocytes. Runx2/Cbfa1 and the housekeeping gene beta-actin were expressed in all osteoblast-like cell types (Fig. 5A).

No expression of either Sp7 isoform was found in a range of primary and cell lines (data not shown). The cell types examined were: pulmonary artery smooth muscle, bronchial smooth muscle, pulmonary foetal fibroblasts, pulmonary adult fibroblasts, placental microvascular endothelial, umbilical vein endothelial, A549 (adenocarcinoma alveolar epithelial), H322 (adenocarcinoma bronchial epithelial), CaCo2 (intestinal epithelial), U87 (glioma), MM96 (melanoma), Epstein-Barr-transformed lymphocytes, HEL (erythroleukaemia).

The expression of Sp7 in a range of adult tissues was examined by RT-PCR using oligo-dT primed cDNAs. Isoform specific expression was not detected. However, using primers located in the 3'UTR that detect both isoforms expression was found in testis, heart, brain, placenta, lung, pancreas, ovary and spleen (Fig. 5B). No expression was detected in liver, muscle, kidney, thymus, prostate, small intestine, colon and leukocytes. Overall, Sp7 mRNA expression was very low, since it required a minimum of 40 cycles of amplification to be detected. Using primers

**Figure 5**

(A) Expression of Sp7 and Runx2/Cbfa1 mRNAs in human cell types by reverse transcriptase PCR. Amplicons were run on an ethidium bromide stained agarose gel. The amplicons were: Sp7 long protein isoform, Sp7L; Sp7 short protein isoform, Sp7S; core binding factor alpha 1, Runx2/Cbfa1 and the housekeeping gene β -actin. The sizes of the amplicons are indicated. The lanes are: primary foetal osteoblasts, FO; primary craniofacial osteoblasts, CF; primary adult osteoblasts, AO; primary adult chondrocytes, CH; HOS osteosarcoma cell line, HS; MG63 osteosarcoma cell line, MG; negative control, (-); positive control, (+) and 100 bp DNA marker, m. (B) Expression of Sp7 mRNA in human adult tissues. The tissues examined were: heart, He; whole brain, Br; placenta, Pl; lung, Lu; liver, Li; skeletal muscle, SM; kidney, Ki; pancreas, Pa; spleen, Sp; thymus, Th; prostate, Pr; testis, Te; ovary, Ov; small intestine, SI; colon, Co; peripheral blood leukocyte, Le.

located in the 3'UTR of another transcription factor, TCF23, [30] no expression was detected under these amplification conditions (data not shown), indicating that the cDNAs were free of genomic DNA.

Discussion

We have cloned two human Sp7 cDNAs that are homologues of the murine Osterix transcription factor [5] that is specifically expressed in all developing bones. As would be expected for a gene involved in bone development, the Sp7 gene has a limited phylogenetic distribution being identified only in mammals, amphibians and teleosts

(bony fish) to date. The long Sp7 protein isoform has 94.7% identity with the murine protein. The Sp7 proteins share a high degree of homology with other members of the Sp family in the three zinc-finger DNA-binding domain. The human Sp7 protein has 78% identity and 89% similarity with human Sp1 protein in the DNA-binding domain, but the two proteins have little homology elsewhere in their sequences. All those residues in the three zinc fingers that are important for maintaining the structure and that contact DNA are conserved between Sp7 and Sp1, indicating that Sp7 will bind Sp1 DNA consensus sites. Indeed, Osterix/Sp7 bound a consensus Sp1

binding site and Sp1-like sequences in the collagen type- $\text{I}\alpha 1$ and collagen type- $2\alpha 1$ promoters [5]. No genetic bone disease has yet been associated to the Sp7 gene [31]. However, we speculate that abnormal Sp7 binding to the polymorphic Sp1 binding site in the collagen type I $\alpha 1$ gene promoter [32] may lead to reduced bone density and osteoporosis.

The human Sp7 gene is separated by 57 kb from the Sp1 gene at chromosomal localisation 12q13.13. This arrangement is similar in the mouse with the genes being separated by 53 kb on a supercontig (Mm15_WIFeb01_286), on chromosome 15 between the Wnt10b and Itga5 genes [5] and leads to the suggestion that the two genes evolved through a duplication event from a common ancestor. However, they are encoded on opposite strands and have very different gene structures, with Sp1 having 6 exons. These two Sp genes are in close proximity to the HOX-C gene cluster. Colocalization between Sp genes and HOX gene clusters is a reoccurring feature of the genome [33]. In humans, Sp2 and Sp6 are linked to the HOX-B gene cluster located on chromosome 17q21.3-q22 and Sp3 and Sp5 are linked to the HOX-D gene cluster located on chromosome 2q31.1 and Sp4 is linked to the HOX A gene cluster located on chromosome 7q21.3-q22. Together, the combination of Sp and homeobox genes may form a genome unit in which transcription of these genes is co-ordinated since they are all involved in determining the pattern of development.

Both the human and rodent Sp7 genes have a similar structure, spanning 9.7 kb and having three exons with the first two exons being alternatively spliced. The two alternatively spliced human Sp7 cDNAs encode a full-length protein (alpha or long isoform) and an amino-terminal truncated protein (beta or short isoform) of 431 and 413 residues respectively. This arrangement is also found in the homologous rodent genes. Alternative spliced variants are a feature of other members of the Sp/XKLF family [34]. TIEG, an oestrogen regulated protein in osteoblasts, has 2 isoforms that are expressed from alternative promoters in a similar manner to Sp7 [35–37]. The isoforms are called the TGF β -inducible early gene (TIEG1) and the early growth response gene- α (TIEG2). TIEG1 possesses an extra 10 residues at its amino-terminus. Alternative isoforms of other family members may possess different transcriptional properties since different Sp3 isoforms can stimulate or repress transcription [38,39].

We have shown that the relative abundance of the two Sp7 isoforms varies in different cell types. There are some potential transcription factor binding sites that are conserved in the promoter regions of the human and rodent Sp7 genes. These may be important in regulating the expression of the different Sp7 isoforms. Close to the start

of transcription of the short protein isoform are overlapping S8 homeobox transcription factor and Runx2/Cbfa1, OSE2 elements [40–42]. The S8 homeobox transcription factor is involved in mesenchyme-specific pattern formation in the embryo, and Runx2/Cbfa1 is essential for osteoblast differentiation [41,43]. In mice, Runx2/Cbfa1 acts upstream of Sp7 in bone development [5] so the presence of a conserved OSE2 element suggests that Runx2/Cbfa1 may directly regulate the expression of the short protein isoform of Sp7. Runx2/Cbfa1 has two amino-terminal isoforms which exert different functions in the process of osteoblast differentiation [13,44,45]. However, the role of these isoforms in regulating Sp7 expression remains to be determined. The presence of a CCAAT box, a potential NF-Y binding site close to the start of transcription of the long protein isoform, suggests that expression of this isoform may be regulated by NF-Y in a similar manner to the way that bone sialoprotein expression is stimulated by the NF-Y transcription factor [46].

Human Sp7 mRNA expression was limited to cells of the mesenchymal lineage such as foetal and craniofacial osteoblasts, chondrocytes and the osteosarcoma cell lines HOS and MG63. Similarly, in mice and rat cell lines Sp7/osterix expression was found in the preosteoblastic cell line, MC3T3-E1, but not in fibroblasts, nor plasmacytoma or pheochromocytoma cells [5]. The expression pattern of Sp7 supports the idea that this transcription factor plays a role in both osteoblast differentiation in both endochondral and intramembranous ossification since it was expressed in foetal osteoblasts and neonatal craniofacial osteoblasts.

Adult osteoblasts expressed Runx2/Cbfa1, which acts upstream of Sp7 [5]. However, Sp7 expression was below the level of detection in these cells. It remains to be determined whether loss of Sp7 expression is the result of partial de-differentiation in the *in vitro* culture conditions or reflects the situation in aged bone. Adults constantly remodel bone and a possible consequence of a loss of Sp7 expression in human adult osteoblasts may be a reduction in bone mineralization. Potential treatments that increase Sp7 expression may help treat bone-wasting diseases such as osteoporosis.

Human articular chondrocytes also expressed Runx2/Cbfa1 and Sp7. In mice embryos, Sp7/osterix is expressed in young differentiating chondrocytes and germ tooth mesenchymal cells, but not in condensed chondrogenic mesenchyme nor in later chondrocytic cells [5]. Rat chondrosarcoma cells were also found to express Sp7/osterix. This suggests that Sp7 plays a role in chondrocyte differentiation, but not in cartilage matrix deposition.

Osteosarcomas are primary malignant tumours of bone or soft parts arising from bone-forming mesenchymal cells. Sp7 was expressed in both the 2 human osteosarcoma cell lines examined and has previously been found in the rat osteosarcoma cell line, ROS17/2.8, [5]. Additionally, amplification of chromosomal region 12q13-15 that contains Sp7 has been noted in various human osteosarcoma [47,48] suggesting that Sp7 may be involved in neoplastic disease.

Conclusions

The expression of Sp7 in human primary foetal osteoblast cells involved in endochondral and intramembranous ossification is consistent with a role for Sp7 in the coordination of changes in transcription required to generate bone formation. However, expression of Sp7 in chondrocytes suggests that it also plays a role in cartilage formation. Two different promoters generate two alternatively spliced isoforms, the proximal promoter generating the full-length protein and the distal promoter an amino-terminal truncated short protein isoform. Generally, the short protein isoform was more abundant.

Methods

Cell culture and RNA extraction

Two cell lines derived from osteosarcomas, Hos and MG-63, [49,50] were a kind gift from Colin Scotchford (University of Nottingham). They were cultured at 37°C in 5% CO₂ using Dulbecco's Modified Eagle's Medium, containing 4 mM L-glutamine, 4500 mg glucose/L, 1500 mg bicarbonate/L (Invitrogen, UK) with the addition of 10% foetal bovine serum, 10 µM ascorbic acid, 100 IU/mL penicillin and 50 µg/mL streptomycin. Primary human osteoblasts were isolated from trabecular bone of femoral heads taken during total hip arthroplasty and cultured as previously described [51]. Primary human craniofacial osteoblasts were obtained from paediatric skull and cultured as previously described [52]. Human primary foetal osteoblasts were obtained and cultured as previously described [53]. Human primary articular chondrocytes were obtained from isolated femoral heads and cultured as previously described [54]. Total RNA was extracted from cells using the SV Total RNA Isolation System, (Promega, UK). The concentration and purity of eluted RNA was determined spectrophotometrically and the quality of the RNA was verified by non-denaturing agarose gel electrophoresis. For Sp7 cloning, total RNA was reverse transcribed with an oligo-dT primer using ThermoScript, an AMV RNase H-reverse transcriptase (Invitrogen, UK).

Molecular cloning of human Sp7

The mouse Osterix/Sp7 cDNA sequence [5] was used to search the human genome sequence and the EST database to identify the human homologue of Sp7. PCR primers

designed from the sequence of genomic DNA clone RP11-147A18 and an EST (accession No. BM687008) was used to clone two alternative spliced isoforms of the human Sp7 cDNA by PCR from foetal osteoblast cDNA. The PCR primers were: forward, long protein isoform A, TCTCTCCATCTGCCTGG; forward, short protein isoform B, ACCCGTTGCCTGCACTCTC and common reverse, CACAATGTTCTCTCCCAAGCT (Helena Biosciences, France). RT and PCR were carried out in a thermocycler (PE Applied Biosystems 2400) using Advantage cDNA polymerase (Clontech, UK). PCR products were excised from agarose gels stained with ethidium bromide and eluted from the agarose using a DNA extraction kit (Qiagen, UK). The PCR products were cloned into the T-A vector pCR4-TOPO (Invitrogen, The Netherlands). Transformed colonies were picked and vectors containing inserts were extracted using the Wizard Plus SV minipreps DNA purification system (Promega, UK) and sequenced in both directions as previously described [55].

Tissue and cellular distribution of human Sp7 mRNA by reverse transcriptase PCR

Human cDNA was analysed for the relative expression of the Sp7, Runx2/Cbfa1 and β-actin mRNA by real time PCR. Sixteen adult tissue cDNAs (BD Clontech, UK) were generated from polyA⁺ selected RNA and reverse transcribed using an oligo-dT primer. Cell type cDNAs were generated from total RNA and reverse transcribed using random hexamers. Approximately 4.0 ng of cDNA from each tissue, and cDNA derived from 50 ng of total RNA from each cell type was amplified by PCR using Taq Gold polymerase. Tissue master mixes were divided into gene specific mixes with the addition of PCR primers to a final concentration of 200 µM. The primers were: Sp7 3'UTR, TTGACTGCAGAGCAGGTTCTT and GCTGCAAGCTCTC-CATAACCA producing a 97 bp amplicon; Sp7 forward primer for the long protein isoform, TCCTCCCTGCTTGAGGAGGA(exon 1b/2); Sp7 forward primer for the short protein isoform, CAGGTTCCCCAGGAGGA(exon 1a/2) and common reverse primer, AGTCCGCAGAGGGCTAGAG (exon 2) producing a 100 and 98 bp amplicons respectively; Runx2/Cbfa1, AGAAGAGCCAGGCAGGTGCT(exon 6/7) and TTCGTGGGTTGGAGAAGCG (exon 7) producing a 102 bp amplicon, a measure of the sum of all Runx2/Cbfa1 isoforms, and β-actin, GGCCACGGCTGCTTC and GTTGGCGTACAGGCTTTTGC producing a 208 bp amplicon. The amplification conditions were; a 10 min hot start to activate the polymerase followed by 50 cycles of 95°C for 15 sec and 60°C for 1 min. Amplification specificity was confirmed by agarose gel electrophoresis and direct sequencing of the amplicons.

Authors' Contributions

AJE conceived of the study, and participated in its design and coordination. MAM and JEG carried out the cell culture work, MAM carried out the expression studies and MAM and AJE carried out the gene cloning. All authors participated in writing the manuscript, read, and approved the final manuscript.

Acknowledgements

We thank the Advanced Biotechnology Centre for DNA sequencing (Charing Cross Campus, Imperial College, London), Drs Bruce Knight and Chris Murphy for providing primary foetal osteoblasts and adult chondrocytes respectively and June Edgar for critically reading the manuscript.

References

- Katagiri T and Takahashi N: **Regulatory mechanisms of osteoblast and osteoclast differentiation.** *Oral Dis* 2002, **8**:147-159.
- Xynos ID, Edgar AJ, Buttery LD, Hench LL and Polak JM: **Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis.** *Biochem Biophys Res Commun* 2000, **276**:461-465.
- Buttery LD, Bourne S, Xynos JD, Wood H, Hughes FJ, Hughes SP, Episkopou V and Polak JM: **Differentiation of osteoblasts and in vitro bone formation from murine embryonic stem cells.** *Tissue Eng* 2001, **7**:89-99.
- Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN and O'Keefe RJ: **Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair.** *J Clin Invest* 2002, **109**:1405-1415.
- Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR and de Crombrughe B: **The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.** *Cell* 2002, **108**:17-29.
- Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A and Karsenty G: **Increased bone formation in osteocalcin-deficient mice.** *Nature* 1996, **382**:448-452.
- Karsenty G: **Bone formation and factors affecting this process.** *Matrix Biol* 2000, **19**:85-89.
- Torrunguang K, Shah R, Alvarez M, Bowen DK, Gerard R, Pavalko FM, Elmendorf JS, Charoonpatrapong K, Hock J, Rhodes SJ and Bidwell JP: **Osteoblast intracellular localization of Nmp4 proteins.** *Bone* 2002, **30**:931-936.
- Jheon A, Chen J, Teo W, Ganss B, Sodek J and Cheifetz S: **Temporal and spatial expression of a novel zinc finger transcription factor, AJ18, in developing murine skeletal tissues.** *J Histochem Cytochem* 2002, **50**:973-982.
- Jheon AH, Ganss B, Cheifetz S and Sodek J: **Characterization of a novel KRAB/C2H2 zinc finger transcription factor involved in bone development.** *J Biol Chem* 2001, **276**:18282-18289.
- Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S and Kishimoto T: **Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.** *Cell* 1997, **89**:755-764.
- Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB and Owen MJ: **Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development.** *Cell* 1997, **89**:765-771.
- Harada H, Tagashira S, Fujiwara M, Ogawa S, Katsumata T, Yamaguchi A, Komori T and Nakatsuka M: **Cbfa1 isoforms exert functional differences in osteoblast differentiation.** *J Biol Chem* 1999, **274**:6972-6978.
- Yagi K, Tsuji K, Nifuji A, Shinomiya K, Nakashima K, DeCrombrughe B and Noda M: **Bone morphogenetic protein-2 enhances osterix gene expression in chondrocytes.** *J Cell Biochem* 2003, **88**:1077-1083.
- Philipsen S and Suske G: **A tale of three fingers: the family of mammalian Sp/XKLF transcription factors.** *Nucleic Acids Res* 1999, **27**:2991-3000.
- Black AR, Black JD and Azizkhan-Clifford J: **Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer.** *J Cell Physiol* 2001, **188**:143-160.
- Gollner H, Dani C, Phillips B, Philipsen S and Suske G: **Impaired ossification in mice lacking the transcription factor Sp3.** *Mech Dev* 2001, **106**:77-83.
- Kolell KJ and Crawford DL: **Evolution of Sp transcription factors.** *Mol Biol Evol* 2002, **19**:216-222.
- Dynan WS and Tjian R: **Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II.** *Cell* 1983, **32**:669-680.
- Suske G: **The Sp-family of transcription factors.** *Gene* 1999, **238**:291-300.
- Yoo J, Jeong MJ, Kwon BM, Hur MW, Park YM and Han MY: **Activation of dynamin I gene expression by Sp1 and Sp3 is required for neuronal differentiation of NIE-115 cells.** *J Biol Chem* 2002, **277**:11904-11909.
- Ghayor C, Chadjichristos C, Herrouin JF, Ala-Kokko L, Suske G, Pujol JP and Galera P: **Sp3 represses the Sp1-mediated transactivation of the human COL2A1 gene in primary and de-differentiated chondrocytes.** *J Biol Chem* 2001, **276**:36881-36895.
- Chadjichristos C, Ghayor C, Herrouin JF, Ala-Kokko L, Suske G, Pujol JP and Galera P: **Down-regulation of human type II collagen gene expression by transforming growth factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio.** *J Biol Chem* 2002, **277**:43903-43917.
- Harrison SM, Houzelstein D, Dunwoodie SL and Beddington RS: **Sp5, a new member of the Sp1 family, is dynamically expressed during development and genetically interacts with Brachyury.** *Dev Biol* 2000, **227**:358-372.
- Kozak M: **An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.** *Nucleic Acids Res* 1987, **15**:8125-8148.
- Hoof van Huijsduijnen R, Li XY, Black D, Matthes H, Benoist C and Mathis D: **Co-evolution from yeast to mouse: cDNA cloning of the two NF-Y (CP-1/CBF) subunits.** *Embo J* 1990, **9**:3119-3127.
- Kawai J, Shinagawa A, Shibata K, Yoshino M, Itoh M, Ishii Y, Arakawa T, Hara A, Fukunishi Y, Konno H, Adachi J, Fukuda S, Aizawa K, Izawa M, Nishi K, Kiyosawa H, Kondo S, Yamanaka I, Saito T, Okazaki Y, Gojibori T, Bono H, Kasukawa T, Saito R, Kadota K, Matsuda H, Ashburner M, Batalov S, Casavant T, Fleischmann W, Gaasterland T, Gissi C, King B, Kochiwa H, Kuehl P, Lewis S, Matsuo Y, Nikaido I, Pesole G, Quackenbush J, Schriml LM, Staubli F, Suzuki R, Tomita M, Wagner L, Washio T, Sakai K, Okido T, Furuno M, Aono H, Baldarelli R, Barsh G, Blake J, Boffelli D, Bojunga N, Carninci P, de Bonaldo MF, Brownstein MJ, Bult C, Fletcher C, Fujita M, Gariboldi M, Gustincich S, Hill D, Hofmann M, Hume DA, Kamiya M, Lee NH, Lyons P, Marchionni L, Mashima J, Mazzarelli J, Mombaerts P, Nordone P, Ring B, Ringwald M, Rodriguez I, Sakamoto N, Sasaki H, Sato K, Schonbach C, Seya T, Shibata Y, Storch KF, Suzuki H, Toyo-oka K, Wang KH, Weitz C, Whittaker C, Wilming L, Wynshaw-Boris A, Yoshida K, Hasegawa Y, Kawaji H, Kohtsuki S and Hayashizaki Y: **Functional annotation of a full-length mouse cDNA collection.** *Nature* 2001, **409**:685-690.
- Narayan VA, Kriwacki RW and Caradonna JP: **Structures of zinc finger domains from transcription factor Sp1. Insights into sequence-specific protein-DNA recognition.** *J Biol Chem* 1997, **272**:7801-7809.
- Gashler AL, Swaminathan S and Sukhatme VP: **A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1.** *Mol Cell Biol* 1993, **13**:4556-4571.
- Tachibana M, Narumi O, Murguruma K, Yamamoto I, Shinkai Y and Yokota Y: **Genomic organization and chromosomal mapping of the basic helix-loop-helix factor OUT (Tcf23/TCF23).** *Cytogenet Cell Genet* 2001, **94**:23-25.
- Yang X and Karsenty G: **Transcription factors in bone: developmental and pathological aspects.** *Trends Mol Med* 2002, **8**:340-345.
- Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP, Aspden RM and Ralston SH: **A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality.** *J Clin Invest* 2001, **107**:899-907.

33. Kalff-Suske M, Kunz J, Grzeschik KH and Suske G: **Human Sp3 transcriptional regulator gene (SP3) maps to chromosome 2q31.** *Genomics* 1996, **37**:410-412.
34. Takahara T, Kanazu SI, Yanagisawa S and Akanuma H: **Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of homotypic trans-splicing.** *J Biol Chem* 2000, **275**:38067-38072.
35. Subramaniam M, Harris SA, Oursler MJ, Rasmussen K, Riggs BL and Spelsberg TC: **Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts.** *Nucleic Acids Res* 1995, **23**:4907-4912.
36. Blok LJ, Kumar MV and Tindall DJ: **Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR.** *Prostate* 1995, **26**:213-224.
37. Tau KR, Hefferan TE, Waters KM, Robinson JA, Subramaniam M, Riggs BL and Spelsberg TC: **Estrogen regulation of a transforming growth factor-beta inducible early gene that inhibits deoxyribonucleic acid synthesis in human osteoblasts.** *Endocrinology* 1998, **139**:1346-1353.
38. Kennett SB, Udvadia AJ and Horowitz JM: **Sp3 encodes multiple proteins that differ in their capacity to stimulate or repress transcription.** *Nucleic Acids Res* 1997, **25**:3110-3117.
39. Ge Y, Matherly LH and Taub JW: **Transcriptional regulation of cell-specific expression of the human cystathionine beta-synthase gene by differential binding of Sp1/Sp3 to the -1b promoter.** *J Biol Chem* 2001, **276**:43570-43579.
40. de Jong R, van der Heijden J and Meijlink F: **DNA-binding specificity of the S8 homeodomain.** *Nucleic Acids Res* 1993, **21**:4711-4720.
41. Wang SW and Speck NA: **Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers.** *Mol Cell Biol* 1992, **12**:89-102.
42. Ducey P and Karsenty G: **Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene.** *Mol Cell Biol* 1995, **15**:1858-1869.
43. Ducey P, Zhang R, Geoffroy V, Ridall AL and Karsenty G: **Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.** *Cell* 1997, **89**:747-754.
44. Dhamija S and Krebsbach PH: **Role of Cbfa1 in ameloblastin gene transcription.** *J Biol Chem* 2001, **276**:35159-35164.
45. Banerjee C, Javed A, Choi JY, Green J, Rosen V, van Wijnen AJ, Stein JL, Lian JB and Stein GS: **Differential regulation of the two principal Runx2/Cbfa1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype.** *Endocrinology* 2001, **142**:4026-4039.
46. Kim RH and Sodek J: **Transcription of the bone sialoprotein gene is stimulated by v-Src acting through an inverted CCAAT box.** *Cancer Res* 1999, **59**:565-571.
47. Szymanska J, Mandahl N, Mertens F, Tarkkanen M, Karaharju E and Knuutila S: **Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined cytogenetic and comparative genomic hybridization study.** *Genes Chromosomes Cancer* 1996, **16**:31-34.
48. Lopes MA, Nikitakis NG, Ord RA and Sauk J, Jr.: **Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws.** *Oral Oncol* 2001, **37**:566-571.
49. McAllister RM, Gardner MB, Greene AE, Bradt C, Nichols WW and Landing BH: **Cultivation in vitro of cells derived from a human osteosarcoma.** *Cancer* 1971, **27**:397-402.
50. Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA and De Somer P: **Human interferon: mass production in a newly established cell line, MG-63.** *Antimicrob Agents Chemother* 1977, **12**:11-15.
51. Xynos ID, Edgar AJ, Buttery LD, Hench LL and Polak JM: **Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution.** *J Biomed Mater Res* 2001, **55**:151-157.
52. Gough JE, Christian P, Scotchford CA, Rudd CD and Jones IA: **Synthesis, degradation, and in vitro cell responses of sodium phosphate glasses for craniofacial bone repair.** *J Biomed Mater Res* 2002, **59**:481-489.
53. Harris SA, Enger RJ, Riggs BL and Spelsberg TC: **Development and characterization of a conditionally immortalized human fetal osteoblastic cell line.** *J Bone Miner Res* 1995, **10**:178-186.
54. Murphy CL and Sambanis A: **Effect of oxygen tension and alginate encapsulation on restoration of the differentiated phenotype of passaged chondrocytes.** *Tissue Eng* 2001, **7**:791-803.
55. Edgar AJ: **The human L-threonine 3-dehydrogenase gene is an expressed pseudogene.** *BMC Genet* 2002, **3**:18.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

